"A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - POSEIDON"

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

December 31, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
BCR-ABL Positive Acute Lymphoblastic Leukemia
Trial Locations (10)

18057

University Hospital Rostock, Rostock

31059

University Cancer Institute Oncopole, Toulouse

33000

University Hospital Bordeaux, Bordeaux

38700

University Hospital Grenoble, Grenoble

49100

University Hospital Angers, Angers

69361

University Hospital Lyon, Lyon

80080

University Hospital Amiens, Amiens

81377

University Hospital Munich, Munich

128 00

Ihbt/Úhkt, Prague

06120

University Hospital Halle/Saale, Halle

All Listed Sponsors
lead

Incyte Biosciences International Sàrl

INDUSTRY

NCT03515785 - "A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - POSEIDON" | Biotech Hunter | Biotech Hunter